Details of the Drug

General Information of Drug (ID: DMWFHMZ)

Drug Name
Aminoglutethimide
Synonyms
Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
Indication
Disease Entry ICD 11 Status REF
Cushing disease 5A70 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 232.28
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
95% of drug becomes completely available to its intended biological destination(s) [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.5 +/- 1.6 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 71.89454 micromolar/kg/day [7]
Chemical Identifiers
Formula
C13H16N2O2
IUPAC Name
3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
Canonical SMILES
CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
InChI
InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
InChIKey
ROBVIMPUHSLWNV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2145
ChEBI ID
CHEBI:2654
CAS Number
125-84-8
DrugBank ID
DB00357
TTD ID
D0M6DO
INTEDE ID
DR2260
ACDINA ID
D00834

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [8]
Cholesterol desmolase (CYP11A1) TTSYVO6 CP11A_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cushing disease
ICD Disease Classification 5A70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cholesterol desmolase (CYP11A1) DTT CYP11A1 1.09E-47 -0.41 -1.12
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aminoglutethimide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mifepristone DMGZQEF Moderate Increased metabolism of Aminoglutethimide caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [19]
Osilodrostat DMIJC9X Moderate Increased metabolism of Aminoglutethimide caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [20]
Coadministration of a Drug Treating the Disease Different from Aminoglutethimide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Increased metabolism of Aminoglutethimide caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Glibenclamide DM8JXPZ Minor Increased metabolism of Aminoglutethimide caused by Glibenclamide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Pioglitazone DMKJ485 Minor Increased metabolism of Aminoglutethimide caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Nateglinide DMLK2QH Minor Increased metabolism of Aminoglutethimide caused by Nateglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Glipizide DMZA5PQ Minor Increased metabolism of Aminoglutethimide caused by Glipizide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Midostaurin DMI6E0R Moderate Increased metabolism of Aminoglutethimide caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [23]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Aminoglutethimide caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [24]
Oliceridine DM6MDCF Major Increased metabolism of Aminoglutethimide caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [25]
Donepezil DMIYG7Z Moderate Increased metabolism of Aminoglutethimide caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [26]
Ivabradine DM0L594 Moderate Increased metabolism of Aminoglutethimide caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [27]
Dronedarone DMA8FS5 Moderate Increased metabolism of Aminoglutethimide caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Bedaquiline DM3906J Moderate Increased metabolism of Aminoglutethimide caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [29]
Buspirone DMBS632 Moderate Increased metabolism of Aminoglutethimide caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [30]
Voriconazole DMAOL2S Moderate Increased metabolism of Aminoglutethimide caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [31]
Montelukast DMD157S Moderate Increased metabolism of Aminoglutethimide caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [32]
Aminophylline DML2NIB Moderate Increased metabolism of Aminoglutethimide caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [33]
Telithromycin DMZ4P3A Moderate Increased metabolism of Aminoglutethimide caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Cariprazine DMJYDVK Moderate Increased metabolism of Aminoglutethimide caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [27]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Aminoglutethimide caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Moderate Increased metabolism of Aminoglutethimide caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
LY2835219 DM93VBZ Moderate Increased metabolism of Aminoglutethimide caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Exemestane DM9HPW3 Moderate Increased metabolism of Aminoglutethimide caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Aminoglutethimide caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Tucatinib DMBESUA Moderate Increased metabolism of Aminoglutethimide caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Palbociclib DMD7L94 Moderate Increased metabolism of Aminoglutethimide caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Alpelisib DMEXMYK Moderate Increased metabolism of Aminoglutethimide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Aminoglutethimide caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Aminoglutethimide caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Toremifene DMQYUWG Moderate Increased metabolism of Aminoglutethimide caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Bosutinib DMTI8YE Moderate Increased metabolism of Aminoglutethimide caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Estradiol DMUNTE3 Moderate Increased metabolism of Aminoglutethimide caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Atorvastatin DMF28YC Moderate Increased metabolism of Aminoglutethimide caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [45]
Macitentan DMP79A1 Moderate Increased metabolism of Aminoglutethimide caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [46]
PF-04449913 DMSB068 Moderate Increased metabolism of Aminoglutethimide caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [47]
Irinotecan DMP6SC2 Moderate Increased metabolism of Aminoglutethimide caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [48]
Drospirenone DM1A9W3 Moderate Increased metabolism of Aminoglutethimide caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [38]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Aminoglutethimide caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [38]
Ulipristal DMBNI20 Moderate Increased metabolism of Aminoglutethimide caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [27]
Alfentanil DMVO0UB Moderate Increased metabolism of Aminoglutethimide caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [49]
Ivacaftor DMZC1HS Moderate Increased metabolism of Aminoglutethimide caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [50]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Aminoglutethimide caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [51]
Aprepitant DM053KT Moderate Increased metabolism of Aminoglutethimide caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [52]
Vilazodone DM4LECQ Moderate Increased metabolism of Aminoglutethimide caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [53]
Vortioxetine DM6F1PU Moderate Increased metabolism of Aminoglutethimide caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [54]
Mirtazapine DML53ZJ Moderate Increased metabolism of Aminoglutethimide caused by Mirtazapine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [55]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Aminoglutethimide caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [44]
Carbamazepine DMZOLBI Moderate Increased metabolism of Aminoglutethimide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Praziquantel DMOU1PK Moderate Increased metabolism of Aminoglutethimide caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [57]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Aminoglutethimide caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [58]
Tazemetostat DMWP1BH Moderate Increased metabolism of Aminoglutethimide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [59]
Solifenacin DMG592Q Moderate Increased metabolism of Aminoglutethimide caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [60]
Mirabegron DMS1GYT Minor Increased metabolism of Aminoglutethimide caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [61]
Darifenacin DMWXLYZ Moderate Increased metabolism of Aminoglutethimide caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [62]
Ripretinib DM958QB Moderate Increased metabolism of Aminoglutethimide caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [35]
Sunitinib DMCBJSR Moderate Increased metabolism of Aminoglutethimide caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [35]
Avapritinib DMK2GZX Moderate Increased metabolism of Aminoglutethimide caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Ergotamine DMKR3C5 Moderate Increased metabolism of Aminoglutethimide caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [35]
MK-1439 DM215WE Moderate Increased metabolism of Aminoglutethimide caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Delavirdine DM3NF5G Moderate Increased metabolism of Aminoglutethimide caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Aminoglutethimide caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Fostemsavir DM50ILT Minor Increased metabolism of Aminoglutethimide caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Tipranavir DM8HJX6 Moderate Increased metabolism of Aminoglutethimide caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Efavirenz DMC0GSJ Moderate Increased metabolism of Aminoglutethimide caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Dolutegravir DMCZGRE Minor Increased metabolism of Aminoglutethimide caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Saquinavir DMG814N Moderate Increased metabolism of Aminoglutethimide caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Etravirine DMGV8QU Moderate Increased metabolism of Aminoglutethimide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Aminoglutethimide caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Atazanavir DMSYRBX Moderate Increased metabolism of Aminoglutethimide caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Maraviroc DMTL94F Moderate Increased metabolism of Aminoglutethimide caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Ritonavir DMU764S Moderate Increased metabolism of Aminoglutethimide caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Tolvaptan DMIWFRL Moderate Increased metabolism of Aminoglutethimide caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [27]
Suvorexant DM0E6S3 Moderate Increased metabolism of Aminoglutethimide caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
Ramelteon DM7IW9J Moderate Increased metabolism of Aminoglutethimide caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [70]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Aminoglutethimide caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Aminoglutethimide caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [72]
ITI-007 DMUQ1DO Major Increased metabolism of Aminoglutethimide caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [73]
Zolpidem DMWOSKJ Moderate Increased metabolism of Aminoglutethimide caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
Naloxegol DML0B41 Moderate Increased metabolism of Aminoglutethimide caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [74]
Pemigatinib DM819JF Moderate Increased metabolism of Aminoglutethimide caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [75]
Crizotinib DM4F29C Moderate Increased metabolism of Aminoglutethimide caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Brigatinib DM7W94S Moderate Increased metabolism of Aminoglutethimide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Erlotinib DMCMBHA Moderate Increased metabolism of Aminoglutethimide caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [77]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Aminoglutethimide caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [78]
Osimertinib DMRJLAT Moderate Increased metabolism of Aminoglutethimide caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Capmatinib DMYCXKL Moderate Increased metabolism of Aminoglutethimide caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Selpercatinib DMZR15V Moderate Increased metabolism of Aminoglutethimide caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [20]
Artemether DM48QOT Moderate Increased metabolism of Aminoglutethimide caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [35]
Quinine DMSWYF5 Moderate Increased metabolism of Aminoglutethimide caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [81]
Mefloquine DMWT905 Moderate Increased metabolism of Aminoglutethimide caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [82]
Idelalisib DM602WT Moderate Increased metabolism of Aminoglutethimide caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
GDC-0199 DMH0QKA Moderate Increased metabolism of Aminoglutethimide caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
IPI-145 DMWA24P Moderate Increased metabolism of Aminoglutethimide caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Aminoglutethimide caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ibrutinib DMHZCPO Moderate Increased metabolism of Aminoglutethimide caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [87]
Vincristine DMINOX3 Moderate Increased metabolism of Aminoglutethimide caused by Vincristine mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [88]
Ponatinib DMYGJQO Moderate Increased metabolism of Aminoglutethimide caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [35]
Vemurafenib DM62UG5 Moderate Increased metabolism of Aminoglutethimide caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [89]
Selumetinib DMC7W6R Moderate Increased metabolism of Aminoglutethimide caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [90]
LGX818 DMNQXV8 Moderate Increased metabolism of Aminoglutethimide caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [91]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Aminoglutethimide caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [44]
Ubrogepant DM749I3 Moderate Increased metabolism of Aminoglutethimide caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [92]
Flibanserin DM70DTN Moderate Increased metabolism of Aminoglutethimide caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [93]
Panobinostat DM58WKG Moderate Increased metabolism of Aminoglutethimide caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [94]
Nilotinib DM7HXWT Moderate Increased metabolism of Aminoglutethimide caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [95]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Aminoglutethimide caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [96]
Dasatinib DMJV2EK Moderate Increased metabolism of Aminoglutethimide caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Modafinil DMYILBE Moderate Increased metabolism of Aminoglutethimide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [97]
Rolapitant DM8XP26 Moderate Increased metabolism of Aminoglutethimide caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [98]
E-2007 DMJDYNQ Moderate Increased metabolism of Aminoglutethimide caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [27]
Entrectinib DMMPTLH Moderate Increased metabolism of Aminoglutethimide caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [27]
Olaparib DM8QB1D Moderate Increased metabolism of Aminoglutethimide caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [35]
Butorphanol DM5KYPJ Major Increased metabolism of Aminoglutethimide caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [99]
Buprenorphine DMPRI8G Moderate Increased metabolism of Aminoglutethimide caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [100]
Hydrocodone DMQ2JO5 Major Increased metabolism of Aminoglutethimide caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [99]
Oxycodone DMXLKHV Major Increased metabolism of Aminoglutethimide caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [99]
Pimavanserin DMR7IVC Moderate Increased metabolism of Aminoglutethimide caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [101]
Macimorelin DMQYJIR Moderate Increased metabolism of Aminoglutethimide caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [102]
Lefamulin DME6G97 Moderate Increased metabolism of Aminoglutethimide caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [103]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Aminoglutethimide caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [104]
Progesterone DMUY35B Moderate Increased metabolism of Aminoglutethimide caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [38]
Enzalutamide DMGL19D Moderate Increased metabolism of Aminoglutethimide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [105]
Darolutamide DMV7YFT Moderate Increased metabolism of Aminoglutethimide caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [106]
Silodosin DMJSBT6 Moderate Increased metabolism of Aminoglutethimide caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [35]
Apremilast DMTWS9E Moderate Increased metabolism of Aminoglutethimide caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [107]
Riociguat DMXBLMP Moderate Increased metabolism of Aminoglutethimide caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [108]
Everolimus DM8X2EH Moderate Increased metabolism of Aminoglutethimide caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [35]
Axitinib DMGVH6N Moderate Increased metabolism of Aminoglutethimide caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [109]
Temsirolimus DMS104F Moderate Increased metabolism of Aminoglutethimide caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [35]
Sorafenib DMS8IFC Moderate Increased metabolism of Aminoglutethimide caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [110]
Tofacitinib DMBS370 Moderate Increased metabolism of Aminoglutethimide caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [35]
Dexamethasone DMMWZET Moderate Increased metabolism of Aminoglutethimide caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [22]
Quetiapine DM1N62C Moderate Increased metabolism of Aminoglutethimide caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [35]
Aripiprazole DM3NUMH Moderate Increased metabolism of Aminoglutethimide caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [111]
Fentanyl DM8WAHT Major Increased metabolism of Aminoglutethimide caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [99]
Avanafil DM75CXN Moderate Increased metabolism of Aminoglutethimide caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [112]
Tadalafil DMJZHT1 Moderate Increased metabolism of Aminoglutethimide caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [27]
LDE225 DMM9F25 Moderate Increased metabolism of Aminoglutethimide caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [113]
Larotrectinib DM26CQR Moderate Increased metabolism of Aminoglutethimide caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Vinblastine DM5TVS3 Moderate Increased metabolism of Aminoglutethimide caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
Docetaxel DMDI269 Moderate Increased metabolism of Aminoglutethimide caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [114]
Trabectedin DMG3Y89 Moderate Increased metabolism of Aminoglutethimide caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Armodafinil DMGB035 Moderate Increased metabolism of Aminoglutethimide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [97]
LEE011 DMMX75K Moderate Increased metabolism of Aminoglutethimide caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Norethindrone DMTY169 Moderate Increased metabolism of Aminoglutethimide caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Taxol DMUOT9V Moderate Increased metabolism of Aminoglutethimide caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [115]
Doxorubicin DMVP5YE Moderate Increased metabolism of Aminoglutethimide caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Vinorelbine DMVXFYE Moderate Increased metabolism of Aminoglutethimide caused by Vinorelbine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
Warfarin DMJYCVW Moderate Increased metabolism of Aminoglutethimide caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [22]
Fostamatinib DM6AUHV Moderate Increased metabolism of Aminoglutethimide caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [20]
Apixaban DM89JLN Moderate Increased metabolism of Aminoglutethimide caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [116]
Brilinta DMBR01X Moderate Increased metabolism of Aminoglutethimide caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [99]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Aminoglutethimide caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [117]
Sirolimus DMGW1ID Moderate Increased metabolism of Aminoglutethimide caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [35]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Aminoglutethimide caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [35]
Tolbutamide DM02AWV Minor Increased metabolism of Aminoglutethimide caused by Tolbutamide mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [22]
Saxagliptin DMGXENV Moderate Increased metabolism of Aminoglutethimide caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [118]
Chlorpropamide DMPHZQE Minor Increased metabolism of Aminoglutethimide caused by Chlorpropamide mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [22]
Linagliptin DMWFJTR Moderate Increased metabolism of Aminoglutethimide caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [119]
Elagolix DMB2C0E Moderate Increased metabolism of Aminoglutethimide caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [120]
⏷ Show the Full List of 159 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Aminoglutethimide 250mg tablet 250mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7054).
2 Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
9 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
10 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
11 Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
12 Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
13 Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
14 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
15 Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
16 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
18 Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
19 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
20 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
21 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
22 Kvinssland S, Lonning PE, Ueland PM "Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects." Breast Cancer Res Treat 7 (1986): s73-6. [PMID: 2943339]
23 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
24 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
25 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
26 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
29 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
30 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
31 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
32 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
33 Lonning PE, Kvinnsland S, Bakke OM "Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer." Clin Pharmacol Ther 36 (1984): 796-802. [PMID: 6499359]
34 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
35 Cerner Multum, Inc. "Australian Product Information.".
36 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
37 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
38 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
39 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
40 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
41 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
42 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
43 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
45 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
46 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
49 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
50 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
51 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
52 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
53 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
54 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
55 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
56 Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497]
57 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
58 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
59 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
60 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
61 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
62 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
64 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
65 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
66 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
67 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
68 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
69 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
70 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
71 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
72 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
73 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
74 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
76 Cerner Multum, Inc. "Canadian Product Information.".
77 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
78 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
79 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
81 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
82 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
83 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
84 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
85 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
86 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
88 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
89 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
90 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
92 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
93 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
94 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
95 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
96 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
97 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
98 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
99 Canadian Pharmacists Association.
100 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
101 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
102 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
103 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
104 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
105 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
106 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
107 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
108 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
109 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
110 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
111 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
112 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
113 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
114 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
115 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
116 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
117 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
118 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
119 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
120 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.